Entering text into the input field will update the search result below

Novavax's mid-stage study of RSV vaccine candidate poised to start; shares ahead 18%

Feb. 15, 2017 11:59 AM ETNovavax, Inc. (NVAX) StockBy: Douglas W. House, SA News Editor35 Comments
  • Novavax (NASDAQ:NVAX +18.3%) is up on more than double normal volume. No particular news accounts for the action. Last month, it initiated a Phase 2 clinical trial assessing the safety and immunogenicity of its F-protein nanoparticle RSV F Vaccine in adults at least 60 years old.
  • The 300-subject study will evaluate the performance of one- and two-dose regimens of RSV F Vaccine with and without aluminum phosphate or the company's Matrix-M adjuvant. Top-line data are expected in Q3.
  • RSV infection is a significant risk for older people, affecting 2.5M Americans each year causing 207K hospitalizations and 16K deaths. There are currently no RSV vaccines commercially available.

Recommended For You

About NVAX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVAX--
Novavax, Inc.